Dermavant Sciences
- Company typePrivate
- Founded2016
- HeadquartersLong Beach, United States
- Headcount251–500
- GTM typeB2B
- OfferingHardware or Manufacturing
Dermavant Sciences firmographics
Firmographics- Name
- Dermavant Sciences
- Legal name
- Dermavant Sciences Ltd.
- Website
- https://dermavant.com
- Company type
- Private
- Founded year
- 2016
- Operating status
- Acquired
- Headcount range
- 251–500 employees
- Ownership category
- akta.pro rank
Dermavant Sciences industry classification
Industry- Product category
- Dermatology Pharmaceuticals
- akta.pro primary industry
- Dermatology Specialty Pharmaceuticals (HLAIACAL)
- akta.pro secondary industries
- Psoriasis & Eczema Specialty Care (HLAKACAL), Dermatology & Aesthetics Pharmaceuticals (HLAIAAAK)
Keywords
Where Dermavant Sciences is headquartered
LocationHeadquarters
- HQ city
- Long Beach
- HQ country
- United States
- HQ region
- North America
Markets served
Dermavant Sciences business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Marketing or Sales, Operations, Supply Chain
Dermavant Sciences product offering
Product offeringCore offering
Dermavant Sciences is a biopharmaceutical company focused on developing and commercializing innovative topical therapeutics for dermatological conditions. Its core product is Tapinarof cream (branded VTAMA), a prescription therapeutic cream indicated for plaque psoriasis and atopic dermatitis. The company operates in the dermatology segment of the pharmaceutical industry, targeting conditions with significant unmet patient need.
Product overview
Dermavant Sciences is a biopharmaceutical company specializing in immunodermatology. The company's primary product is tapinarof, a therapeutic cream for the treatment of psoriasis and atopic dermatitis. Tapinarof is Dermavant's core pipeline asset that received FDA approval. Dermavant was acquired by Organon & Co. in October 2024 for up to approximately $1.2 billion, and tapinarof (marketed as VTAMA) is now part of Organon's dermatology portfolio alongside their broader general medicines franchise that includes biosimilars and treatments for cardiovascular, neurology, autoimmune, and respiratory conditions.
Differentiator
Problem solved
Functional benefit
Products and services
- Tapinarof cream (VTAMA)
Companies that use Dermavant Sciences
Customer profileSegments1 record
Ideal customer profiles2 records
Dermavant Sciences technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature1 record
Dermavant Sciences partnerships and signals
Strategic signalScale indicators6 records
Recent moves5 records
Expansion highlights4 records
Dermavant Sciences competitors and assessment
Company assessmentDirect peers
- Arcutis Biotherapeutics: Specialty dermatology biopharma that developed and commercializes ZORYVE (roflumilast cream), a topical therapy approved for both plaque psoriasis and atopic dermatitis — directly overlapping Dermavant's tapinarof indications, patient population, and physician channel.
- Galderma: Pure-play dermatology company with a broad portfolio of branded prescription and aesthetic skin therapeutics, including topical and biologic products for psoriasis, atopic dermatitis, and acne. Comparable to Dermavant as a dermatology-specialized commercial entity.
- LEO Pharma: Global dermatology-focused pharmaceutical company marketing branded topicals and systemics across psoriasis, eczema, and actinic keratosis. Directly comparable to Dermavant as a dermatology-specialty commercial competitor.
- Almirall: European dermatology specialty pharma with a portfolio spanning psoriasis, atopic dermatitis, and actinic keratosis. Directly comparable to Dermavant as a dermatology-focused prescription therapeutics company with overlapping indications.
Broad incumbents
- AbbVie: Large biopharma with leading immunology franchise in psoriasis and atopic dermatitis through Skyrizi (risankizumab) and Rinvoq (upadacitinib). Competes with Dermavant in the same dermatologist-prescribed indications via systemic rather than topical mechanisms.
- Bristol Myers Squibb: Marketer of Sotyktu (deucravacitinib), an oral TYK2 inhibitor approved for moderate-to-severe plaque psoriasis. Competes with Dermavant in moderate-to-severe psoriasis via a different mechanism and route of administration.
- Sanofi: Co-developer and marketer of Dupixent (dupilumab) with Regeneron, the leading biologic for atopic dermatitis and a competitor in adjacent Type 2 inflammatory skin indications. Comparable as a dermatology/biologic competitor relevant to tapinarof's atopic dermatitis opportunity.
- Amgen: Markets Otezla (apremilast), an oral PDE4 inhibitor approved for plaque psoriasis, psoriatic arthritis, and oral ulcers in Behçet's disease. Overlaps with Dermavant in plaque psoriasis via systemic mechanism and dermatologist channel.
- Pfizer: Markets Cibinqo (abrocitinib), an oral JAK inhibitor approved for atopic dermatitis, alongside broader inflammation and immunology assets. Competes with Dermavant in moderate-to-severe atopic dermatitis via systemic mechanism.
Emerging players
- AnaptysBio: Clinical-stage immunology biotech developing IL-36R and PD-1 agonist antibodies with potential applications in inflammatory skin disease such as hidradenitis suppurativa and psoriasis. An emerging immunology peer whose inflammatory skin disease pipeline partially overlaps Dermavant's therapeutic focus.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights5 records
Customer concentration
Dermavant Sciences social profiles
Digital presenceDermavant Sciences financial estimates
Financial estimateRevenue estimate
Valuation estimate
Dermavant Sciences leadership team
Management profileNumber of profiles
Profiles3 records
Dermavant Sciences funding detail
Funding detailFunding overview
Funding rounds2 records
Investors3 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Dermavant Sciences M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Dermavant Sciences
What does Dermavant Sciences do?
Dermavant Sciences is a biopharmaceutical company focused on developing and commercializing innovative topical therapeutics for dermatological conditions. Its core product is Tapinarof cream (branded VTAMA), a prescription therapeutic cream indicated for plaque psoriasis and atopic dermatitis. The company operates in the dermatology segment of the pharmaceutical industry, targeting conditions with significant unmet patient need.
Is Dermavant Sciences a public or private company?
Dermavant Sciences is a private company. It is classified as corporate owned and is currently acquired.
When was Dermavant Sciences founded?
Dermavant Sciences was founded in 2016. It employs 251 to 500 people.
Where is Dermavant Sciences based?
Dermavant Sciences is headquartered in Long Beach, United States, in the North America region.
Who are Dermavant Sciences's main competitors?
Direct peers on record are Arcutis Biotherapeutics, Galderma, LEO Pharma and Almirall. Broad incumbents are AbbVie, Bristol Myers Squibb, Sanofi, Amgen and Pfizer. AnaptysBio is listed as an emerging player.
Does Dermavant Sciences have an API?
No public API is recorded for Dermavant Sciences.
What industry is Dermavant Sciences in?
Dermavant Sciences's product category is Dermatology Pharmaceuticals. Its primary akta.pro industry code is HLAIACAL, Dermatology Specialty Pharmaceuticals, with a secondary code of HLAKACAL, Psoriasis & Eczema Specialty Care.